cyrilzakka/clinical-trials huggingface dataset:
Preoperative or Postoperative Therapy of Patients With Stages IB, II, IIIA Non-Small Cell Lung Cancer

In this phase II study, we plan to evaluate several novel components of therapy. In patients with potentially resectable stages IIB (T3N0) and IIIA we will compare weekly paclitaxel and carboplatin with concomitant radiation therapy versus weekly paclitaxel and every 4 week carboplatin in the preoperative (neoadjuvant) setting. For patients with potentially resectable stage IB, IIA and IIB (T2N1) tumors, weekly paclitaxel and every 4 week carboplatin will be given pre-operatively (neoadjuvant). The feasibility of resection will be evaluated in the neoadjuvant group of patients. The continued study of concurrent radiation therapy with weekly paclitaxel and carboplatin will be evaluated in those patients with stage IIB (T3N0) and IIIA disease who initially had resection (adjuvant setting). Lastly, weekly paclitaxel and carboplatin every 4 weeks will be evaluated as an adjuvant program in patients who had completely resected stage IB, IIA and IIB (T2N1).

Upon determination of eligibility, neo-adjuvant patients will be randomly assigned to one of two treatment arms:

* ARM A Paclitaxel + Carboplatin + Radiation Therapy + Surgery
* ARM B Paclitaxel + Carboplatin + Surgery

After surgery neo-adjuvant patients with a complete resection will either receive Paclitaxel + Carboplatin or no therapy, depending on their stage of disease at time of enrollment. Patients with incomplete resection Paclitaxel + Carboplatin + Radiation Therapy. Adjuvant patients who enter the study after complete resection will receive Paclitaxel + Carboplatin with or without Radiation Therapy based on initial stage of disease.

Eligibility Criteria:
Inclusion Criteria:

To be included in this study, you must meet the following criteria:

* Non-small cell lung cancer
* Neoadjuvant candidates must have potentially resectable disease
* Adjuvant candidates must have had complete resection
* Clinical stage IB, II, or IIIA non-small cell lung cancer
* ECOG performance status 0 or 1
* Adequate bone marrow, liver and kidney function
* No previous chemotherapy or radiation therapy for non-small cell lung cancer.
* Give written informed consent.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

* Stage IIIA with N2 nodes \> 6 cm
* Stage IIIB or IV disease
* Age \<18 years
* ECOG performance status 2 or higher
* Considered inoperable based on general medical condition
* History of prior malignancy within five years
* Women who are pregnant or lactating

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Control of Trichomoniasis

This study is designed to try to find the best method of partner notification and treatment for partners of women with trichomonas

To carry out a randomized trial to compare the effectiveness of three methods of partner notification and treatment for sexual partners of women with vaginal trichomoniasis - patient self-referral of partners (the current practice standard), delivery of curative therapy to partners by patients themselves, or public health style Disease Intervention carried out by a specially trained Disease Intervention Specialists (DIS) locating the partners and delivering the medication in the field. Reinfection rates with trichomonas at three months of follow-up among the index women will be the measure of effectiveness.

Eligibility Criteria:
Inclusion Criteria:

Inclusion criteria {for Women}:

Age {\> 15 years} Culture or wet prep proven T. vaginalis infection Willingness to provide informed consent and take part in study procedures

-

Exclusion Criteria:

* Exclusion criteria:

Infection with other STD pathogens requiring Health Dept DIS intervention (syphilis or HIV) Pregnancy or currently breast feeding Recent (8 hours) ingestion of alcoholic beverages or intent to do so in the 24 hours following treatment Allergy to metronidazole The presence of a sexual partner in the clinic at the time of enrollment A history of referral by a partner already treated for trichomoniasis Report of more than four sexual partners in the preceding 30 days
Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.

This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation mechanism of acupuncture intervention on hot flashes based on integrated PET/MRI technology.

This topic combines the theory of "unblocking the governor and warming the yang" with the important findings of modern research, that is, the important mechanism of the spine in the pathogenesis of breast cancer, and innovatively proposes the technique of unblocking the governor and treating the spine. Prospective clinical intervention research in rehabilitation, objectively evaluate the clinical efficacy, advantages and disadvantages of this technology, so as to effectively break through the current application dilemma of acupuncture and bone-setting manipulation in tumor diseases.

Eligibility Criteria:
Inclusion Criteria:

* Aged 30-75 years old;
* Adjuvant hormone therapy (eg, tamoxifen and/or aromatase inhibitors) with or without ovarian function suppression has been administered for at least 4 weeks and is currently on treatment;
* Patients with persistent hot flashes for at least 4 weeks and with a frequency of more than 14 hot flashes per week (2 times per day) in the week before inclusion in the study, the weekly average hot flash composite score is 3-4;
* Patients after surgery and chemotherapy (if any);
* Eastern Cooperative Oncology Group score of 0-1 points.
* Sign the informed consent and participate in the clinical observation voluntarily.

Exclusion Criteria:

* Tumor metastases, undergoing chemoradiotherapy or planning surgery;
* Pharmacological intervention for hot flashes with hot flash treatment drugs such as selective serotonin reuptake inhibitors (SSRIs) and/or anticonvulsants for at least 4 weeks prior to study initiation;
* Patients receiving phytoestrogens, tibolone or analogs, verapril, or specific homeopathic medicines;
* Started or changed adjuvant hormone therapy within the past week, or who planned to start or change adjuvant hormone therapy in the past 14 weeks, pregnant or breastfeeding patients;
* Bleeding or coagulation disorders with obvious uncontrolled infection
* Psychiatric illness or family history; neurological disorder or family history; seizure possibility or history of seizures.
A Follow-up Study of Asymptomatic Infections and Diagnosed Patients With Covid-19 in Shanghai

This study is to clarify the distribution characteristics, host and clinical characteristics, disease outcome and risk factors, changes of multiple organs such as cardiopulmonary function and changes in social and psychological indicators during long-term follow-up of omicron variant asymptomatic infections and diagnosed patients


Eligibility Criteria:
Inclusion Criteria:

* SARS-Cov-2-RNA positive
* informed consent signed

Exclusion Criteria:

* informed consent rejected
Disease Management in Adolescents With Type 1 Diabetes

Adolescence period; It is a transition period of rapid growth, development and maturation in biochemical, physical, social and spiritual terms, which lasts from the beginning of puberty to young adulthood. Adolescence is a predictable developmental transition period for the individual. They also encounter unpredictable situations (such as childhood illnesses). One of these conditions is Type 1 Diabetes Mellitus, which is the most common metabolic endocrine system disease in adolescents. Type 1 diabetes is an important health/disease transition in the life of a child and adolescent. Therefore, this study aimed to determine the effect of the "Adaptation to Adolescence and Type 1 Diabetes Management Training Programme", prepared in line with Meleis's Transition Theory, on the adolescent's developmental transition adaptation, self-efficacy for diabetes management and glycemic control.


Eligibility Criteria:
Inclusion Criteria:

* Having been diagnosed with type 1 diabetes in the last 6 months
* HbA1c level \>7.5

Exclusion Criteria:

* presence of a diagnosis of intellectual disability, autism spectrum disorder and psychotic disorder
Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae

This is a study of the genetics of malaria transmission by the mosquito vector in Africa, Anopheles gambiae. The study focuses on the mosquito vector, not the human subjects infected with malaria. DNA extracted from infected mosquitoes will be analyzed genetically by microsatellite and single-nucleotide polymorphisms (SNPs) to identify mosquito genes that control mosquito resistance to malaria parasites.

A standard diagnostic blood smear from a drop of blood will be carried out on 20 study subjects once per month. One malaria-positive subject from among the 20 will be asked to donate 5cc of blood, also no more frequently than once per month. The blood will be placed in a water-jacketed heated membrane feeding device that will be positioned on top of a cage of mosquitoes. The mosquitoes are attracted to the warmth and drink the blood through the artificial skin-like membrane. The goal of the research is to study the infected mosquitoes. No studies will be carried out on the human subjects. The point of human subjects involvement is to obtain the naturally malaria-infected blood for feeding of mosquitoes. After blood feeding, the mosquitoes are held in an environmental chamber for one week, at which time they are dissected to count numbers of malaria parasites developing on the mosquito stomach wall. This number constitutes the quantitative phenotype, and we extract genomic DNA from the carcass for genetic marker typing, which constitutes the genotype. Genetic linkage analysis identifies markers near genes that control parasite number, thus resistance or susceptibility to parasite infection.

Eligibility Criteria:
Inclusion Criteria:

* 5-10 years old, and general good health

Exclusion Criteria:

* Outside age group
* Specific diagnosable health problems
* General poor health
Topical PH-10 Aqueous Hydrogel and Photodynamic Therapy for Psoriasis

This is an open label, single center, controlled study with each subject's two treatment plaque areas assigned by the investigator 1:1 to (a) PH-10 with ambient light exposure and (b) PH-10 with 544 nm LED light illumination at 10 J/cm2. A third plaque area will receive no treatment and serve as a control.

Subjects with at least three distinct, stable study plaque areas will receive the experimental therapy to two treatment plaque areas twice a week (2-5 days apart) for the lesser of 12 weeks or until remission is observed in the treatment plaque areas. If remission is observed in a treatment plaque area then treatment of that area will be discontinued and the area assessed weekly. A third plaque area (control plaque area) will receive no drug or light treatment and serve as an internal control.

Primary efficacy will be assessed 12 weeks after initial PH-10 treatment. Subjects will be followed for a total of 16 weeks to allow assessment of Durability of Response of treated lesions and comprehensive follow-up of adverse events.


Eligibility Criteria:
Inclusion Criteria:

* Stable, moderate to severe plaque psoriasis in at least three distinct plaque areas, each separated by at least a 2.5-cm band of normal skin. Study plaque areas, each covering a contiguous area up to 15 x 35 cm in size, should have a minimum plaque size of 2 cm2. All study plaque areas must be on the trunk or extremities (excluding palms, soles, scalp, and facial or intertriginous sites).
* Fitzpatrick skin type I-VI.
* Ability to understand and sign the informed consent document.

Exclusion Criteria:

* Female subjects of childbearing potential who are pregnant, attempting to conceive, or nursing an infant.
* Subjects who have received PUVA or UVB light therapy or systemic antipsoriatic therapy within 4 weeks of study treatment (two weeks for methotrexate).
* Subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin, or Vitamin D analogs) to the study plaque areas within 2 weeks of study treatment.
* Subjects who have received any photosensitizing or phototoxic drug within 4 weeks of study treatment.
* Subjects who have received any approved biologic drug therapy for psoriasis within 3 months or 5 half-lives of study treatment.
* Subjects who have participated in a clinical research study within 4 weeks of study treatment.
* Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.
* Subjects with clinical conditions that, in the opinion of the Principal Investigator, may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.
Effect of Dapagliflozin on LV Remodeling Post AMI

The overall hypothesis of the study is that Dapagliflozin will reduce left ventricular remodeling in patients who have had a myocardial infarction.

In patients with heart failure, with or without diabetes, SGLT2i have shown to decrease remodeling. However, this has not been tested in patients following an acute myocardial infarction.

Acute myocardial infarction is serious condition with increasing incidence across the world. Following treatment, a reasonable amount of patients develop remodeling of the left ventricle, which is associated with worse prognosis. This occurs despite patients are treated with GDMT.

Dapagliflozin is an SGLT2i with biological plausibility to decrease left ventricular remodeling following acute myocardial infarction. In the present study, researchers will test the hypothesis that Dapagliflozin will reduce left ventricular remodeling in patients who have had a myocardial infarction (less than 7 days). This will be a randomized, single-blind, placebo controlled trial. The primary endpoint will be the change in end-diastolic and end-systolic left ventricular volumes from baseline to the end of the intervention (6 months). We will include patients with acute myocardial infarction who have been treated with primary PCI.

Eligibility Criteria:
Inclusion Criteria:

* Acute myocardial infarction treated within the 24 hours of beginning of symptoms
* Signed informed consent
* SBP \> 90 mmHg
* Age \>= 18 years

Exclusion Criteria:

* Glomerular Filtration Rate \< 30 ml/min/1.73 m2.
* Pregnant or lactating woman
* Cancer or life-threatening condition
* Use of continuous parental inotropic agents
* Psychiatric disease incompatible with being in study.
* Any contraindication to MRI procedures.
* Any other medical or physical condition considered to be inappropriate by a study physician
* Scheduled for a PCI or CABG within the next 6 months
* Hemodynamic unstability
* Currently on any SGLT2i
* One or more episodes of severe hypoglicemia
* Acute urinary or genital infection
Thermal Comfort of Different Desktop Materials

The aim of this study is to test the suitability of different types of desk surfaces. The investigators will test 10 different surfaces (oak-ruff, oak-varnished, oak-oiled, spruce-ruff, spruce-varnished, spruce-oiled, particleboard laminate, particleboard veneer, corian and glass). Firstly, the investigators will perform tests to assess physical characteristics of the materials (thermal conductivity, hardness, roughness, skid measures). Secondly, the investigators will measure the participants' forearm skin temperature after 20-minutes of using each desk surface. During those 20 minutes the participants will solve an attention test.

People are surrounded by objects that are made of different materials. These materials should be carefully chosen, especially the ones that are in direct contact with user's skin. Office workers are constantly in contact with desk surface (while reading, typing, filling in forms, etc.). Therefore, it is important that the material of desk surface is suitable and properly chosen. It should be both functional and aesthetic. The aim of this study is to evaluate the suitability of different desk surfaces for sedentary workers. The investigators will test 10 different surfaces (oak-ruff, oak-varnished, oak-oiled, spruce-ruff, spruce-varnished, spruce-oiled, particleboard laminate, particleboard veneer, corian and glass). All surfaces will be square shaped (800x800 mm). Firstly, the investigators will perform tests to assess physical characteristics of the materials (thermal conductivity, hardness, roughness, skid measures). Secondly, the investigators will measure the participants' forearm skin temperature after 20-minutes of desk use. Every participant will test all 10 sample desk surfaces (cross-over design). The investigators will use thermal IR camera to measure the temperature of participant's skin surface. The investigators will measure the temperature before and after the contact with desk surface. During those 20 minutes the participant will solve an attention test to assess the impact of different materials on attention. At the end, the participants will answer a questionnaire about the suitability of the material.

Eligibility Criteria:
Inclusion Criteria:

* aged between 18 and 35

Exclusion Criteria:

* pregnancy
* pain presence in any musculoskeletal part \> 3 on 10-level scale
Arthroscopic Ankle Arthrodesis: Measuring Post-operative Pain to Assess the Potential for Outpatient Surgery.

Post-operative pain will be measured using a pain diary for one week post-surgery. The purpose is to test the assumption that the arthroscopic technique leads to less post-operative pain and results in shorter hospital stays when compared to the open technique. It is believed that the arthroscopic technique will result in minimal pain when compared to the open technique, allowing this procedure to be performed as day surgery.


Eligibility Criteria:
Inclusion Criteria:

* Ankle osteoarthritis with adequate bone stock

Exclusion Criteria:

* Mental or physical inability to consent or answer pain questions, pre-operative or peri-operative morbidity impairing mobility, pre-operative opioid therapy, non-steroidal anti-inflammatory drugs or steroids within 24 hours before skin incision, kidney or liver dysfunction, morbid obesity, smoking, significant bony deformity, significant loss of bone stock or diabetes with sensory changes will be cause for exclusion.
Quantification of Gluten Peptides in Feces

Treatment for celiac disease (CD) is a lifelong strict gluten-free diet (GFD). Patients should be followed-up with dietary interviews and serologic tests for CD markers to ensure adherence to the diet. However, none of these methods offer an accurate measure of dietary compliance. Our aim was to evaluate the measurement of gluten immunogenic peptides (GIP) in stools as a marker of GFD adherence in CD patients and compare it with traditional methods of GFD monitoring.

We performed a prospective, non-randomized, multicentre study including 188 CD patients on a GFD and 73 healthy controls on a gluten-containing diet. Subjects were given a dietary questionnaire and fecal GIP quantified by ELISA (iVYLISA GIP-S kit). Serological anti-tissue transglutaminase (anti-tTG) IgA and anti-deamidated gliadin peptide (anti-DGP) IgA antibodies were measured simultaneously.


Eligibility Criteria:
Inclusion Criteria:

* The study group consisted of celiac patients following a GFD for at least one year prior to the inclusion in the study and they were required to have an HLA-DQ2 or HLA-DQ8 haplotype and an histologically abnormal duodenal biopsy (grade Marsh IIIB or IIIC) at the time of diagnosis, supported by positive serum anti-endomysium IgA antibodies and/or anti-tissue transglutaminase (anti-tTG) IgA antibodies.
* The positive and negative control groups was comprised of healthy asymptomatic subjects in whom CD had been ruled out and who were not suspected of having any other gastrointestinal condition

Exclusion Criteria:

* All study patients included history of kidney or liver disease, and history of severe psychiatric disease or seizure disorder.
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Dose escalation or repetition will be governed by pre-specified safety and activity rules. Subjects will be confined on days 1-3 and/or days 8-10. Follow-up visits are required periodically through day 43. Subjects with sustained reductions in HbsAg will be requested to return for additional follow-up follow-up visits at 3 and 6 months post last dose. Study procedures involve blood draws for pharmacokinetic, pharmacodynamic, virologic, and safety assessments


Eligibility Criteria:
Inclusion Criteria:

* Chronic HBV infection for ≥ 6 months
* Currently on treatment with at least 1 HBV approved oral drug (i.e. lamivudine, telbivudine, entecavir, adefovir, tenofovir) ≥ 3 months prior to screening
* HBsAg ≥ 250 IU/mL
* HBV DNA at below the level of quantitation (BLQ; to be confirmed at screening)
* Absence of extensive bridging fibrosis (Metavir 3 or greater)or cirrhosis
* Creatinine clearance ≥ 70 mL/min

Exclusion Criteria:

* Co-infection with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV
* History of Gilberts disease
* Laboratory parameters not within defined thresholds for leukopenia, neutropenia, anemia, thrombocytopenia, thyroid-stimulating hormone (TSH), or other evidence of hepatic decompensation
* Diagnosis of autoimmune disease, poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), malignancy, hemoglobinopathy, retinal disease, or patients who are immunosuppressed
* Evidence of hepatocellular carcinoma